Role of miRNA122 in Patients with Chronic Hepatitis C Virus

Mohammed Jassim Mulla AL-Helfi; Syoof Khowman Alwan  AL-Ramahi

doi:10.17605/cajmns.v6i4.2926

Mohammed Jassim Mulla AL-Helfi Al-Qadisiyah University, College of Science
Syoof Khowman Alwan AL-Ramahi Al-Qadisiyah University, College of Science

DOI: https://doi.org/10.17605/cajmns.v6i4.2926

Keywords: miRNA122, microRNA122, HCV, miRNA-122 level, ischemic heart disease, miRNA

Abstract

In this work, the gene expression of microRNAs 122 and 196 in people with chronic hepatitis C is examined. Patients in the virology and dialysis departments of Al-kindi Teaching Hospital in Baghdad and Al-imam Ali Teaching Hospital in Al-sadr City were randomly selected for both sexes and age groups from 2 January to 1 April 2023. Blood samples with 110 negative and 50 positive hepatitis C results. 50 blood samples were used in this study, 25 of which were from hepatitis C patients who had been diagnosed with a quick test and confirmed by an ELISA, and 25 came from healthy controls. miRNA-196 quantitative real-time PCR in hepatitis C patients and healthy individuals. There were 9 (36%), 4 (16%), and 9 (36%), with a patient age range of 33 to 65. There were 4 (16%) patients from rural regions and 21 (84%) individuals with chronic hepatitis C. The frequency distribution of patients based on the prevalence of some chronic diseases revealed that miRNA levels have an impact on them. Examples include diabetes, which affected 20% of patients as opposed to 16% of healthy individuals, chronic heart disease, which affected 16% of patients as opposed to 16% of healthy individuals, and adopted chronic blood pressure disease. Also accepted was hepatitis. 15% of patients abused alcohol, which is comparable to healthy people. Patients with low miRNA-122 levels and healthy controls Healthy controls had 1.60 0.86 mean levels compared to patients' 22.87 18.40 mean levels. Compared to healthy controls, patients had a level that was significantly greater (P 0.01). MiRNA-122 levels were 39.01 33.24 in HCV patients aged 50–59, compared to lower mean values (10.15 6.54) in those aged 40–49. HCV gender differences 122 miRNA levels The average values for men and women were 29,12 25,91 and 15,73 5,71, respectively. In HCV patients with diabetes, miRNA-122 levels were 58.48 41.40 and 13.97 5.81, respectively (P = 0.01). Levels of miRNA-122 and hypertension linked with HCV Its mean values were 16.03 18.06 in non-hypertensive people and 44.52 14.09 in persons with hypertension (P = 0.01). levels of miRNA-122 in ischemic heart disease caused by the HCV Individuals with and without ischemic heart disease had mean values of 49.89 12.34 and 17.72 27.24, respectively (P = 0.01). Significant (P = 0.01) miRNA-122 levels were found in HCV patients who misused alcohol to be 80.13 46.22 and 15.06 13.65, respectively.

References

L. E. Adinolfi, S. Petta, A. L. Fracanzani, R. Nevola, C. Coppola, V. Narciso, et al., "Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct‐acting antiviral therapy: a prospective study," Diabetes, Obesity and Metabolism, vol. 22, no. 12, pp. 2408-2416, 2020.

S. Bajan and G. Hutvagner, "RNA-based therapeutics: from antisense oligonucleotides to miRNAs," Cells, vol. 9, no. 1, p. 137, 2020.

S. Bandiera, S. Pfeffer, T. F. Baumert, and M. B. Zeisel, "miR-122–a key factor and therapeutic target in liver disease," Journal of Hepatology, vol. 62, no. 2, pp. 448-457, 2015.

D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.

L. F. Gebert and I. J. MacRae, "Regulation of microRNA function in animals," Nature Reviews Molecular Cell Biology, vol. 20, no. 1, pp. 21-37, 2019.

K. Gill, H. Ghazinian, R. Manch, and R. Gish, "Hepatitis C virus as a systemic disease: reaching beyond the liver," Hepatology International, vol. 10, pp. 415-423, 2016.

L. Y. Haque, D. A. Fiellin, J. P. Tate, D. Esserman, D. Bhattacharya, A. A. Butt, et al., "Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment," JAMA Network Open, vol. 5, no. 12, pp. e2246604-e2246604, 2022.

U. Harkus, M. Wankell, P. Palamuthusingam, C. McFarlane, and L. Hebbard, "Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data," in Seminars in Cancer Biology, Academic Press, 2022, pp. 1-12.

Heffernan, G. S. Cooke, S. Nayagam, M. Thursz, and T. B. Hallett, "Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model," The Lancet, vol. 393, no. 10178, pp. 1319-1329, 2019.

N. G. Lambert, H. ElShelmani, M. K. Singh, F. C. Mansergh, M. A. Wride, M. Padilla, et al., "Risk factors and biomarkers of age-related macular degeneration," Progress in Retinal and Eye Research, vol. 54, pp. 64-102, 2016.

J. Liu, F. Zhou, Y. Guan, F. Meng, Z. Zhao, Q. Su, et al., "The biogenesis of miRNAs and their role in the development of amyotrophic lateral sclerosis," Cells, vol. 11, no. 3, p. 572, 2022.

J. Luo, M. Chen, H. Huang, T. Yuan, M. Zhang, K. Zhang, and S. Deng, "Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma," OncoTargets and Therapy, pp. 577-583, 2013.

J. Weidner, S. Bartel, A. Kılıç, U. M. Zissler, H. Renz, J. Schwarze, et al., "Spotlight on microRNAs in allergy and asthma," Allergy, vol. 76, no. 6, pp. 1661-1678, 2021.

S. Yu and V. N. Kim, "A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing," Nature Reviews Molecular Cell Biology, vol. 21, no. 9, pp. 542-556, 2020.

M. J. Mulla AL-Helfi, S. K. Alwan AL-Ramahi, "Role of miRNA122 in Patients with Chronic Hepatitis C Virus," Al-Qadisiyah University, College of Science, 2023.